UroGen Pharma Ltd.
URGN
$29.80
-$1.53-4.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -133.23M | -153.49M | -164.64M | -154.97M | -138.43M |
| Total Depreciation and Amortization | 2.57M | 2.41M | 2.04M | 1.67M | 1.33M |
| Total Amortization of Deferred Charges | 0.00 | 0.00 | 0.00 | 1.51M | 0.00 |
| Total Other Non-Cash Items | 21.07M | 17.29M | 20.92M | 19.46M | 23.93M |
| Change in Net Operating Assets | -56.15M | -28.65M | 3.94M | 9.20M | 6.11M |
| Cash from Operations | -165.74M | -162.44M | -137.74M | -123.13M | -107.06M |
| Capital Expenditure | -299.00K | -289.00K | -387.00K | -396.00K | -339.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 67.13M | 61.85M | 94.85M | -43.29M | -59.76M |
| Cash from Investing | 66.83M | 61.56M | 94.46M | -43.69M | -60.09M |
| Total Debt Issued | 65.35M | -- | 0.00 | 24.49M | 24.49M |
| Total Debt Repaid | -2.18M | -1.86M | -- | -- | -- |
| Issuance of Common Stock | 41.92M | 41.77M | 8.67M | 15.52M | 96.87M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 3.00K | 3.00K | 18.64M |
| Cash from Financing | 105.09M | 39.92M | 8.67M | 40.01M | 140.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.19M | -60.97M | -34.60M | -126.81M | -27.15M |